Upcoming Pharming Group dividend
No change
Next payment N/A
Next payment date N/A
Last payment N/A
Last payment date N/A
00 D 00 H 00 M 00 S
Ex-Dividend: N/A
Not available

Dividends from Pharming Group for this year have not been sketched out in their statements.

Pharming Group N.V., listed in the United States, Germany and the Netherlands under the name PHAR, does not pay dividends to its shareholders.

Payout Ratio Pharming Group Dividends

In the last fiscal period, Pharming Group paid no dividends, resulting in a dividend payout ratio of 0%.
Pharming Group has not distributed dividends in the last fiscal period, therefore, the payout ratio is 0%.
Dividend payout ratio
Payout Ratio

Dividend calendar of Pharming Group

There is no Dividend Calendar of Pharming Group defined for 2024.

Information about Pharming Group

Full name Pharming Group N.V.
Ticker PHARM
Sector Health Care
Industry Biotechnology
Market Capitalization 537.07 €
ISIN NL0010391025
Number of Employees 332
Description of the company

Pharming Group N.V., is a company with a worldwide presence dedicated to the biopharmaceutical sector, especially in the research and creation of treatments for rare or uncommon, debilitating diseases with a high mortality rate.

It is headquartered in Leiden, the Netherlands, and New Jersey, USA, but serves approximately 30 markets in Europe, the Middle East, North America, Africa and Asia, with more than 300 employees.

The group focuses on commercializing therapies based on protein replacement, as well as precision medicines, having partners at any level or stakeholder, from patients, healthcare professionals, employees, small laboratories, suppliers, external shareholders, among others.

Among its most representative drugs are RUCONEST® (conestat alfa) and JOENJA® (leniolisib), both approved by the EMA (European Medicines Agency) for marketing in Europe, by the FDA (Food and Drug Administration) for the United States and by the MHRA (Medicines and Healthcare products Regulatory Agency) for the United Kingdom.

Their technological platform is mainly based on the use of rhC1INH, although they are working on the development or acquisition of other methods to be used in their processes, in addition they also have in their platform as part of their services the monitoring and opportunity to report any adverse event, trying to comply with the global health care requirements and to update their products.

In addition, they are developing programs for the treatment of ADPS (sticky platelet syndrome), which is an abnormal, genetic and progressive immunodeficiency, as well as the research, creation and commercialization of OTL-105, a gene therapy that acts with stem cells to treat hereditary angioedema (HAE), which is being developed in collaboration with Orchard Therapeutics.

Frequently asked questions about Pharming Group dividends

Pharming Group is listed on the Bolsa de Amsterdam and is part of the ASCX.

Pharming Group has the Ticker or stock code PHARM.

The CEO of Pharming Group in 2024 is Dr. Sijmen de Vries M.B.A., M.D..

Pharming Group ForumCheck the latest comments and participate in the live chat on Pharming Group stocks (PHARM).
Notify of

Inline Feedbacks
View all comments